Reversible cardiomyopathy secondary to Amphotericin-B

Medical Mycology Case Reports - Tập 13 - Trang 19-21 - 2016
Antonio Carlos Bandeira1, José Magalhães Filho2, Karine de Almeida Ramos2
1Faculdade de Tecnologia e Ciencias Medical School, Hospital Couto Maia, Rua São Francisco s/n Monte Serrat, Zip 40425-060 Salvador, Bahia, Brazil
2Hospital Couto Maia, Rua São Francisco s/n Monte Serrat, Zip 40425-060 Salvador, Bahia, Brazil

Tài liệu tham khảo

Craven, 1985, Risk factors of ventricular fibrillation during rapid amphotericin B infusion, Antimicrob. Agents Chemother., 27, 868, 10.1128/AAC.27.5.868

Arsura, 1994, Amphotericin B-induced dilated cardiomyopathy, Am. J. Med., 97, 560, 10.1016/0002-9343(94)90353-0

Danaher, 2004, Reversible dilated cardiomyopathy related to Amphotericin B, J. Antimicrob. Chemother., 53, 115, 10.1093/jac/dkg472

Moyssakis, 2005, Reversible dilated cardiomyopathy associated with amphotericin B treatment, Int. J. Antimicrob. Agents, 25, 444, 10.1016/j.ijantimicag.2005.02.015

Soares, 2015, Reversible dilated cardiomyopathy associated with amphotericin B therapy, J. Clin. Pharm. Ther., 40, 333, 10.1111/jcpt.12237

Groot, 2008, Acute refractory hyperkalaemia and fatal cardiac arrest related to administration of liposomal amphotericin B, Neth. J. Med., 66, 433

Chung, 1971, Reversible cardiac enlargement during treatment with amphotericin B and hydrocortisone, Am. Rev. Resp. Dis., 103, 831

Thông tin
Thông tin xuất bản

Medical Mycology Case Reports

Tập 13

19-21

Thông tin tác giả